MSFT 453.9631 -2.6353% AAPL 228.225 -2.0409% NVDA 131.2 -2.75% GOOGL 187.56 -1.8935% GOOG 189.16 -1.8167% AMZN 196.37 -1.7118% META 522.38 -2.3023% AVGO 1714.64 -1.7224% TSLA 265.3951 0.811% TSM 187.5 -1.8582% LLY 937.8 -0.2107% V 261.56 -0.5475% JPM 207.67 -0.0626% UNH 505.78 0.9682% NVO 141.2 -1.0789% WMT 69.41 -1.4203% LVMUY 154.5 1.9667% XOM 112.96 0.9292% LVMHF 770.5 1.6491% MA 432.89 -0.173%

Hookipa Pharma Inc

Healthcare US HOOK


Last update at 2024-07-11T14:46:00Z

Day Range


52 Week Range



  • Previous Close 5.50
  • Market Cap77.19M
  • Volume68562
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-46.62500M
  • Revenue TTM53.55M
  • Revenue Per Share TTM0.50
  • Gross Profit TTM -52.96600M
  • Diluted EPS TTM-0.47


Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -64.91500M -75.66500M -44.08200M -43.03700M -16.21300M
Minority interest - - - - -
Net income -65.14500M -75.66600M -33.80100M -34.14700M -16.23700M
Selling general administrative 18.76M 17.27M 18.08M 16.71M 6.84M
Selling and marketing expenses - - - - -
Gross profit 14.25M 18.45M 19.58M 11.94M 7.63M
Reconciled depreciation 3.60M 4.64M 4.15M 1.44M 0.64M
Ebit -76.75700M -86.31400M -57.43500M -52.52800M -15.43500M
Ebitda -73.15500M -81.67400M -53.28500M -51.08500M -14.79500M
Depreciation and amortization 3.60M 4.64M 4.15M 1.44M 0.64M
Non operating income net other 9.16M 6.91M 9.99M - -
Operating income -73.15500M -81.67400M -53.28500M -51.08500M -21.18000M
Other operating expenses 87.40M 100.12M 72.87M 63.03M 23.20M
Interest expense 0.69M 0.90M 0.79M 0.88M 0.78M
Tax provision 0.23M 0.00100M 0.00000M 0.00000M 0.02M
Interest income 1.63M 0.03M 0.40M 1.59M 0.78M
Net interest income 0.95M -0.87100M -0.38600M 0.71M -0.77800M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 0.23M 0.00100M -10.28100M -8.89000M 0.02M
Total revenue 14.25M 18.45M 19.58M 11.94M 7.63M
Total operating expenses 87.40M 100.12M 72.87M 63.03M 23.20M
Cost of revenue - - - 46.31M 21.96M
Total other income expense net 8.24M 6.01M 9.20M 8.05M 0.13M
Discontinued operations - - - - -
Net income from continuing ops -64.91500M -75.66500M -44.08200M -43.03700M -16.23700M
Net income applicable to common shares -64.91500M -75.66500M -44.08200M -43.03700M -16.23700M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 161.34M 170.45M 126.05M 187.82M 143.75M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 10.75M 12.16M 29.32M 23.22M 13.33M
Total liab 71.48M 67.94M 36.45M 31.69M 25.85M
Total stockholder equity 89.86M 102.52M 89.59M 156.12M 117.90M
Deferred long term liab - - - - -
Other current liab 12.05M 10.88M 8.17M 6.35M 8.41M
Common stock 0.01000M 0.00500M 0.00300M 0.00300M 0.00300M
Capital stock 0.01000M 0.00500M 0.00300M 0.00300M 0.00300M
Retained earnings -369.26100M -287.68100M -222.76600M -147.10100M -103.01900M
Other liab - 29.08M 2.67M 1.94M 1.94M
Good will - - - - -
Other assets 0.00000M 1.28M 1.79M 10.09M 1.12M
Cash 117.10M 113.44M 66.91M 143.18M 113.15M
Cash and equivalents - - - - -
Total current liabilities 41.99M 35.63M 27.65M 21.14M 14.76M
Current deferred revenue 14.68M 15.98M 6.23M 4.63M 3.59M
Net debt -110.53700M -106.94100M -56.28700M -132.66800M -102.55200M
Short term debt 2.76M 3.28M 4.50M 2.15M 1.81M
Short long term debt 1.12M 1.59M 2.79M - 1.22M
Short long term debt total 6.56M 6.50M 10.62M 10.51M 10.60M
Other stockholder equity 467.04M 397.35M 317.13M 309.29M 81.82M
Property plant equipment - 17.97M 16.35M 13.97M 14.60M
Total current assets 147.12M 147.20M 102.14M 171.50M 128.02M
Long term investments - - - - -
Net tangible assets - 102.52M 89.59M 156.12M 117.90M
Short term investments - - - - -
Net receivables 19.27M 22.01M 21.17M 20.66M 9.73M
Long term debt - 0.91M 2.22M 4.54M 3.50M
Inventory - -0.41900M -15.26200M -15.54900M -8.19000M
Accounts payable 12.50M 5.49M 8.76M 8.01M 0.94M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -7.93300M -7.15600M -4.78000M -6.06700M -4.65300M
Additional paid in capital - - - - -
Common stock total equity - 0.00500M 0.00300M 0.00300M 0.00300M
Preferred stock total equity - - - - -
Retained earnings total equity - -287.68100M -222.76600M -147.10100M -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.58M 1.28M 1.79M 2.34M 1.12M
Deferred long term asset charges - - - - -
Non current assets total 14.22M 23.26M 23.91M 16.31M 15.73M
Capital lease obligations 5.44M 4.00M 5.61M 5.97M 7.26M
Long term debt total - 0.91M 2.22M 4.54M 3.86M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments -5.01700M -12.58100M -2.37100M -1.99900M -2.15000M
Change to liabilities 2.06M 5.22M 6.81M -0.23900M 12.00M
Total cashflows from investing activities -5.01700M -12.58100M -2.37100M -1.99900M -2.15000M
Net borrowings -3.02000M -0.43800M -1.41900M -2.27900M 0.42M
Total cash from financing activities 72.27M -0.23500M 73.42M 109.75M 6.87M
Change to operating activities 2.94M -4.19800M -11.35000M -3.52000M -7.28400M
Net income -64.91500M -75.66500M -44.08200M -43.03700M -16.23700M
Change in cash 46.53M -76.26500M 29.60M 65.00M -12.78200M
Begin period cash flow 66.91M 143.18M 113.58M 48.58M 61.36M
End period cash flow 113.44M 66.91M 143.18M 113.58M 48.58M
Total cash from operating activities -19.99700M -66.01600M -39.33900M -41.73100M -14.99800M
Issuance of capital stock 75.32M 0.20M 75.06M 112.03M 6.45M
Depreciation 3.60M 4.64M 4.15M 1.44M 0.64M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - -4.19800M -11.35000M -3.52000M -7.28400M
Change to account receivables -0.34100M -1.94300M -3.57600M -3.61900M -4.99100M
Sale purchase of stock 75.32M 0.20M 75.06M 112.03M 6.86M
Other cashflows from financing activities 29.43M -12.58100M 32.20M 37.27M 6.86M
Change to netincome 5.20M 8.87M 8.29M 5.25M 0.87M
Capital expenditures 5.02M 12.58M 2.37M 2.00M 2.15M
Change receivables -0.34100M -1.94300M -3.57600M - -
Cash flows other operating 34.40M -7.13600M -10.51300M - -
Exchange rate changes - - - - -
Cash and cash equivalents changes 47.26M -78.83200M 31.71M - -
Change in working capital 36.11M -3.86100M -8.11700M -7.37800M -0.27500M
Stock based compensation 5.04M 7.64M 8.66M 5.57M 0.87M
Other non cash items 0.16M 1.23M 0.05M 1.68M 0.00700M
Free cash flow -25.01400M -78.59700M -41.71000M -43.73000M -17.14800M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
Hookipa Pharma Inc
0.25 4.55% 5.75 - - 3.87 0.87 1.91 0.42
Novo Nordisk A/S
-1.54 1.08% 141.20 41.58 31.15 2.13 32.99 2.11 4.70
Novo Nordisk A/S
-0.09 0.06% 141.25 41.06 31.25 2.08 33.11 2.11 4.70
Vertex Pharmaceuticals Inc
-1.14 0.23% 490.48 29.67 24.33 10.38 5.83 9.33 20.00
Regeneron Pharmaceuticals Inc
10.39 0.97% 1081.52 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News


HOOKIPA Pharma Inc., a clinical stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-200 for the treatment of pembrolizumab which is in Phase 2 of clinical trial; HB-700, a preclinical development for treatment of KRAS mutated cancers, including lung, colorectal, and pancreatic cancers. Its lead product candidates are HB-400 for the treatment of Hepatitis B which is in Phase I of clinical trial and HB-500 for the treatment of HIV which is in Phase I of clinical trial. The company's preclinical stage products include HB-300 program for prostate cancer. It has a collaboration with Gilead Sciences, Inc. to collaborate on preclinical research programs to evaluate potential vaccine products using or incorporating its replicating and non-replicating technology platforms for the treatment, cure, diagnosis, or prevention of Hepatitis B Virus. HOOKIPA Pharma Inc. was incorporated in 2011 and is headquartered in New York, New York.

Hookipa Pharma Inc

350 Fifth Avenue, New York, NY, United States, 10118

Key Executives

Name Title Year Born
Mr. Joern Aldag CEO & Director 1959
Dr. Reinhard Kandera Ph.D. CFO & Director 1969
Prof. Rolf M. Zinkernagel M.D., Ph.D. Co-Founder 1944
Mr. Andreas Bergthaler Co-Founder NA
Mr. Lukas Flatz Co-Founder NA
Ms. Christine D. Baker M.B.A. Chief Operating Officer 1965
Dr. Klaus Orlinger Ph.D. Chief Scientific Officer 1978
Ms. Marine Popoff Communications & Investor Relations Mang. NA
Mr. Matthew L. S. Beck Exec. Director of Investor Relations NA
Mr. Michael Szumera Exec. Director of Communications NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.